Company profile
Protalix BioTherapeutics, Inc.
AMEX: PLX · Healthcare · Biotechnology
#427 of 1,418 Healthcare companies by revenue39th-percentile growth
EA Score
66BFH 71DQ 64GM 51SS 77
v0.1 · 65/100 weight · provisional
↑ disclosure history, Piotroski F · ↓ filing timeliness, revenue growth (YoY)
Methodology →Revenue TTM
$76.4M
Rev growth YoY (TTM)
+27.8%
Net income (FY)
-$6.6M
Employees
226
as of 2026-08-14
Market cap
$190.1M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$52.7M$52.7M2025
Net income-$6.6M-$6.6M2025
Operating income-$5.5M-$5.5M2025
Total assets$82.3M$82.3M2025
Liabilities$34.1M$34.1M2025
Equity$48.2M$48.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product98%
License and Service2%
By geography
Not disclosed.
The read
What is Protalix BioTherapeutics, Inc.’s revenue?
Protalix BioTherapeutics, Inc. booked $52.7M in FY2025 revenue, contracting 1.2% year over year — slower than 61% of Healthcare companies we track, at a -12.5% net margin.
Peers · Healthcare
Invivyd, Inc.41DRegional Health Properties, Inc.67BApyx Medical Corporation64CIRIDEX Corporation55C1CM Inc.70BONE Bio Corp.——Neighbors
Bergen →Key facts
CEODror Bashan
SectorHealthcare
IndustryBiotechnology
HeadquartersHackensack, NJ
ExchangeAMEX: PLX
Employees226
IPO date1998-05-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.